title: Toward a general evolutionary theory of oncogenesis.
abstract: We propose an evolutionary framework, the barrier theory of cancer, which is based on the distinction between barriers to oncogenesis and restraints. Barriers are defined as mechanisms that prevent oncogenesis. Restraints, which are more numerous, inhibit but do not prevent oncogenesis. Processes that compromise barriers are essential causes of cancer; those that interfere with restraints are exacerbating causes. The barrier theory is built upon the three evolutionary processes involved in oncogenesis: natural selection acting on multicellular organisms to mold barriers and restraints, natural selection acting on infectious organisms to abrogate these protective mechanisms, and oncogenic selection which is responsible for the evolution of normal cells into cancerous cells. The barrier theory is presented as a first step toward the development of a general evolutionary theory of cancer. Its attributes and implications for intervention are compared with those of other major conceptual frameworks for understanding cancer: the clonal diversification model, the stem cell theory and the hallmarks of cancer. The barrier theory emphasizes the practical value of distinguishing between essential and exacerbating causes. It also stresses the importance of determining the scope of infectious causation of cancer, because individual pathogens can be responsible for multiple essential causes in infected cells.
authors: Department of Biology, University of Louisville Louisville, KY, USA.
authors: Paul W
authors: PW
authors: Ewald
authors: Holly A
authors: HA
authors: Swain Ewald
keywords: adaptation; cancer; evolutionary medicine; host parasite interactions; oncogenesis, tumor viruses
references: Lancet. 1995 Jun 24;345(8965):1591-4
references: 7783535
references: Apoptosis. 2008 Mar;13(3):343-53
references: 18253836
references: Prog Biophys Mol Biol. 2011 Aug;106(2):353-79
references: 21736894
references: Neoplasia. 2011 May;13(5):393-405
references: 21532880
references: Cold Spring Harb Symp Quant Biol. 2005;70:383-8
references: 16869775
references: Int Rev Cytol. 1998;177:1-56
references: 9378615
references: Cancer Res. 2006 Oct 1;66(19):9339-44
references: 16990346
references: Nat Clin Pract Oncol. 2009 Jan;6(1):43-52
references: 18982000
references: Nat Rev Cancer. 2012 Jun 14;12(7):487-93
references: 22695393
references: Blood. 1994 Apr 15;83(8):2038-44
references: 8161775
references: J Natl Cancer Inst. 1996 Aug 21;88(16):1152-7
references: 8757195
references: Dev Cell. 2010 Jun 15;18(6):884-901
references: 20627072
references: Nat Rev Cancer. 2004 Nov;4(11):839-49
references: 15516957
references: Nat Rev Cancer. 2006 Dec;6(12):924-35
references: 17109012
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Immunotherapy. 2011 Mar;3(3):407-21
references: 21395382
references: PLoS One. 2011;6(11):e26100
references: 22125594
references: Lancet Oncol. 2002 Apr;3(4):244-51
references: 12067687
references: EMBO J. 2009 May 6;28(9):1296-307
references: 19339992
references: Cell. 2012 Jul 20;150(2):264-78
references: 22817890
references: Cell Stem Cell. 2010 Feb 5;6(2):175-81
references: 20144789
references: Aging Cell. 2008 Dec;7(6):813-23
references: 18778411
references: Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4614-23
references: 17003459
references: J Cell Biochem. 2009 Apr 1;106(5):745-9
references: 19184979
references: Semin Cancer Biol. 2010 Jun;20(3):161-8
references: 20470890
references: J Theor Biol. 1980 Sep 7;86(1):169-76
references: 7464170
references: Nat Med. 2008 May;14(5):518-27
references: 18438415
references: Lancet Oncol. 2009 Apr;10(4):321-2
references: 19350698
references: Nature. 2004 Nov 18;432(7015):332-7
references: 15549095
references: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):358-66
references: 15623796
references: Cancer Immunol Immunother. 2011 Mar;60(3):319-26
references: 21267721
references: Biochemistry (Mosc). 2008 May;73(5):498-503
references: 18605974
references: Cancer Prev Res (Phila). 2011 Jul;4(7):1135-44
references: 21490131
references: Trends Ecol Evol. 2011 Apr;26(4):175-82
references: 21296451
references: Science. 2003 Sep 12;301(5639):1547-50
references: 12970569
references: Cancer. 1999 Sep 15;86(6):1056-63
references: 10491534
references: Cell. 2006 Mar 24;124(6):1111-5
references: 16564000
references: Blood. 2002 Jun 1;99(11):4122-30
references: 12010816
references: Blood. 2000 Nov 15;96(10):3343-56
references: 11071626
references: Lancet Oncol. 2012 Jun;13(6):607-15
references: 22575588
references: Science. 1976 Oct 1;194(4260):23-8
references: 959840
references: Science. 1995 Nov 24;270(5240):1326-31
references: 7481820
references: Adv Parasitol. 2009;68:21-43
references: 19289189
references: Nature. 2011 Mar 24;471(7339):467-72
references: 21430775
references: Nat Rev Cancer. 2008 Jan;8(1):56-61
references: 18059462
references: Nat Rev Cancer. 2002 Mar;2(3):161-74
references: 11990853
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Nat Rev Genet. 2010 Oct;11(10):685-96
references: 20847746
references: N Engl J Med. 2009 Dec 17;361(25):2449-60
references: 20018966
references: Cancer Res. 2011 Jun 1;71(11):3739-44
references: 21610109
references: Science. 1982 Sep 10;217(4564):998-1003
references: 7112116
references: Carcinogenesis. 2000 Mar;21(3):505-15
references: 10688871
references: Cell. 2012 May 25;149(5):994-1007
references: 22608083
references: Trends Ecol Evol. 2005 Oct;20(10):545-52
references: 16701433
references: J Mol Med (Berl). 2012 May;90(5):535-41
references: 22476248
references: Nature. 2012 Jan 18;481(7381):306-13
references: 22258609
references: Nat Clin Pract Oncol. 2005 Feb;2(2):90-7; quiz 1 p following 113
references: 16264881